Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.52 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30294180 | 1.00 | CCNA2 (0.52) | CCNA2CDK2MAPTPIM1PIM2 | |
| SCHEMBL29964392 | 0.83 | MAPT (0.38) | CCNA2CDK2MAPTPIM1PIM2 | |
| SCHEMBL28948723 | 0.83 | CCNA2 (0.41) | CCNA2CDK2PIM1PIM2HTR2A | |
| SCHEMBL31584245 | 0.79 | CCNA2 (0.44) | CCNA2CDK2MAPTHTR2AMEN1 | |
| SCHEMBL31584251 | 0.76 | CCNA2 (0.42) | CCNA2CDK2MAPTHTR2AMEN1 | |
| SCHEMBL785706 | 0.75 | MAPT (0.63) | CCNA2CDK2MAPTDDB1CRBN | |
| SCHEMBL12497878 | 0.75 | CCNA2 (0.51) | CCNA2CDK2MAPTHTR2ADDB1 | |
| SCHEMBL3400140 | 0.75 | PIM1 (0.40) | MAPTPIM1PIM2BUB1MEN1 | |
| SCHEMBL30684862 | 0.75 | PIM1 (0.40) | MAPTPIM1PIM2BUB1MEN1 | |
| SCHEMBL18743044 | 0.74 | GRM5 (0.43) | CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103367-A1 | LIGAND-DRUG CONJUGATE, LINKER FOR CONJUGATION, AND USE THEREOF | 海南先声再明医药股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4161928-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| EP-3478685-B1 | CHIRAL HETEROCYCLIC COMPOUND WITH HEDGEHOG PATHWAY ANTAGONIST ACTIVITY, METHOD AND USE THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-01-12 | — | — | EP | disclosed |
| EP-3478685-B1 | CHIRAL HETEROCYCLIC COMPOUND WITH HEDGEHOG PATHWAY ANTAGONIST ACTIVITY, METHOD AND USE THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| US-10919889-B2 | Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2021-02-16 | — | — | US | disclosed |
| US-10919889-B2 | Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2021-02-16 | — | — | US | disclosed |
| EP-2945623-B1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2018-09-05 | — | — | EP | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2945623-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou yunxuan yiyaokeji youxiangongsi (Su Zhou Yuan Pharm) (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | ATXN2, ATXN2L, ATXN10 | CCNA2 36/4885CDK2 8/4885MAPT 1860/4885 |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | CCNA2 3162/4885CDK2 1488/4885MAPT 3091/4885 |
| US-10919889-B2 | Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof | SHH, GLI1, SMO | CCNA2 1464/4885CDK2 427/4885MAPT 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.